These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 38073228)

  • 1. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan.
    Hagino T; Yoshida M; Hamada R; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2023 Dec; 34(1):2276043. PubMed ID: 38073228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
    Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis.
    Hagino T; Yoshida M; Hamada R; Fujimoto E; Saeki H; Kanda N
    J Dermatol; 2023 Dec; 50(12):1576-1584. PubMed ID: 37665111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatol; 2023 Jul; 50(7):869-879. PubMed ID: 36890685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
    Hagino T; Hamada R; Yoshida M; Fujimoto E; Saeki H; Kanda N
    Clin Cosmet Investig Dermatol; 2023; 16():3201-3212. PubMed ID: 37953857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2024 Dec; 35(1):2344591. PubMed ID: 38653561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T; Saeki H; Kanda N
    J Dermatol; 2022 Nov; 49(11):1158-1167. PubMed ID: 35986480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
    Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2023 Dec; 34(1):2212095. PubMed ID: 37203177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
    Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
    Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    Clin Exp Dermatol; 2024 Oct; ():. PubMed ID: 39378322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis.
    Hagino T; Yoshida M; Hamada R; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2024 Dec; 35(1):2291317. PubMed ID: 38073560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.